Introduction {#sec1}
============

Pain evoked in response to potentially tissue-damaging stimuli is essential for the maintenance of our physical integrity. It can, however, have a severe impact on our well-being when it occurs spontaneously or in response to inappropriate stimuli. It is widely accepted that the spinal dorsal horn, which constitutes the first site for synaptic processing in the pain pathway, serves a critical role for maintaining a physiological level of pain sensitivity. Conversely, maladaptive changes at this site contribute critically to a wide variety of pain pathologies ([@bib34; @bib48; @bib64; @bib69]). The concept of the dorsal horn as a first site to control the modality and intensity of sensory signals conveyed to higher CNS centers dates back to Wall and Melzack's gate control theory of pain ([@bib38]). According to their theory, inhibitory dorsal horn interneurons would constitute the physical basis of this pain gate. They would become activated primarily by input from (non-nociceptive) low-threshold myelinated sensory nerve fibers and would, in turn, control the activity of spinal output neurons.

Early work with antagonists of inhibitory neurotransmitter receptors has demonstrated that exaggerated pain responses can be triggered by blocking inhibitory neurotransmission in the spinal cord ([@bib10; @bib36; @bib51; @bib53; @bib67]). More recent work has suggested that diminished inhibitory control over dorsal horn sensory circuits leads to increased excitability and spontaneous activity of dorsal horn neurons ([@bib20; @bib55]) and allows the excitation of normally pain-specific neurons by inappropriate (non-nociceptive) signals ([@bib7; @bib32; @bib61]; for a review see [@bib48]). A large body of evidence, meanwhile, indicates that diminished synaptic inhibition also occurs naturally in the course of inflammatory and neuropathic syndromes through various mechanisms ([@bib69]).

Inhibitory interneurons make up about one-third of the total neuronal population in the spinal dorsal horn. These neurons use either γ-aminobutyric acid (GABA) or glycine or both for fast neuronal inhibition. In the superficial dorsal horn, i.e., in the termination area of nociceptors, the majority of inhibitory neurons are purely GABAergic, whereas those in the deep dorsal horn are mainly mixed GABA/glycinergic neurons ([@bib60]; for a review, see [@bib69]). Despite recent progress ([@bib21]), the circuits and interneuron types contributing to spinal pain control are still not completely understood. A detailed and comprehensive analysis has so far been hampered by the lack of appropriate molecular tools. Such studies became feasible with the advent of sophisticated viral vector-based approaches and Cre transgenic mouse lines. These technologies allow the functional and morphological mapping of neuronal circuits through retrograde tracing starting from precisely defined neuron populations ([@bib63]) and the manipulation of specific subsets of neurons through ablation, silencing, and excitation in a spatially highly precise manner ([@bib9]).

To specifically address the role of the glycinergic neuron population in the dorsal horn, we generated a bacterial artificial chromosome (BAC) transgenic mouse line that expresses the Cre recombinase selectively in glycinergic neurons. Retrograde tracing experiments showed that glycinergic dorsal horn neurons receive sensory input mainly from low-threshold myelinated dorsal root ganglion (DRG) neurons. Local unilateral ablation of glycinergic neurons with diphtheria toxin or silencing of these neurons with tetanus toxin over three lumbar segments induced mechanical, heat, and cold hyperalgesia and signs of spontaneous aversive behavior, including extensive localized biting reminiscent of chronic itch. Accordingly, selective and local activation of glycinergic neurons alleviated nocifensive responses to acute noxious stimuli, hyperalgesia in neuropathic mice, and chloroquine- and histamine-induced itch responses.

Results {#sec2}
=======

Generation of GlyT2::Cre BAC Transgenic Mice {#sec2.1}
--------------------------------------------

To specifically and locally manipulate glycinergic neurons, we generated a BAC transgenic mouse that expresses the Cre recombinase under the transcriptional control of the *GlyT2* gene, a marker of glycinergic neurons ([@bib45]). We used the same strategy as employed previously for a GlyT2::eGFP BAC transgenic mouse ([@bib68]; [Figure 1](#fig1){ref-type="fig"}A), whose eGFP expression pattern precisely recapitulated the distribution of glycinergic neurons ([@bib27; @bib68]). To characterize the spinal pattern of GlyT2::Cre-dependent recombination, we generated triple transgenic mice carrying the GlyT2::eGFP and GlyT2::Cre transgenes together with a *ROSA26*^LacZ^ reporter. We found a nearly complete match of β-galactosidase (β-gal) expression with GlyT2::eGFP in the deep dorsal horn, whereas the majority of superficial dorsal horn β-gal+ neurons lacked GlyT2::eGFP ([Figures 1](#fig1){ref-type="fig"}B and 1C). However, when the actual Cre protein expression pattern was analyzed in adult mice, an almost complete overlap of Cre and eGFP expression was found throughout the dorsal horn. Both were most abundant in the deep dorsal horn but largely absent from the superficial layers, suggesting that expression of the β-gal reporter in the superficial dorsal horn was caused by transient Cre expression during development ([Figures 1](#fig1){ref-type="fig"}D and 1E). To further confirm eutopic Cre expression, we demonstrate that nearly all (93.7% ± 1.5%) Cre+ neurons also stain positive for Pax2, a transcription factor expressed by more than 90% of adult spinal *Gad67*^eGFP^ and GlyT2::eGFP neurons ([Figures 1](#fig1){ref-type="fig"}F--1H; [Figure S1](#app2){ref-type="sec"}). In the deep dorsal and ventral horn, almost 90% of Pax2+ neurons also expressed Cre, whereas this coexpression dropped to 20% in laminae I/II ([Figures 1](#fig1){ref-type="fig"}F--1H), which corresponds well with the spinal distribution of glycinergic neurons ([@bib60]). The 20% Cre+ neurons of laminae I/II included most of the neuronal nitric oxide synthase (nNOS)+ inhibitory neurons in these laminae ([Figure S2](#app2){ref-type="sec"}).

Primary Sensory Input onto Dorsal Horn Glycinergic Interneurons {#sec2.2}
---------------------------------------------------------------

The preferential localization of glycinergic neurons in the deep dorsal horn (i.e., in the termination areas of non-nociceptive primary sensory neurons) is consistent with what has been proposed in the gate control theory, but unequivocal proof for the innervation by non-nociceptive primary sensory neurons is lacking. Here we used a two-step rabies virus-based retrograde monosynaptic tracing strategy involving an EnvA pseudotyped eGFP rabies virus and TVA expression from a Cre-dependent adeno-associated virus (AAV) to map neurons presynaptic to dorsal horn glycinergic neurons ([Figures 2](#fig2){ref-type="fig"}A and 2B). Seven days after rabies virus injection, we found between 30 and 40 primary rabies virus-infected (TVA+/eGFP+) cells per spinal cord section ([Figure S3](#app2){ref-type="sec"}) and numerous eGFP+ neurons in three to four adjacent lumbar DRGs ipsilateral to the virus injection site ([Figure 2](#fig2){ref-type="fig"}C), demonstrating the presence of direct synaptic input from primary sensory neurons onto glycinergic dorsal horn neurons. Ninety-one percent of these neurons (851 of 934) were myelinated (NF200+), including 7.6% (49 of 641) peptidergic (CGRP+/NF200+) neurons. Only 4.2% were NF200−/CGRP+ (27 of 641) and only 0.15% (1 of 664) were NF200+/IB4+ ([Figures 2](#fig2){ref-type="fig"}D--2F). These results are consistent with strong innervation of dorsal horn glycinergic neurons by non-nociceptive sensory neurons.

Local Ablation of Dorsal Horn Glycinergic Neurons through AAV-Mediated Conditional Toxin Expression {#sec2.3}
---------------------------------------------------------------------------------------------------

To specifically and locally ablate spinal glycinergic neurons, we used intraspinal injections of serotype 1 AAV carrying a conditional (Cre-dependent) diphtheria toxin A fragment (DTA) expression cassette (AAV.flex.DTA; [Figures 3](#fig3){ref-type="fig"}A and 3B). Serotype 1 was chosen because retrograde infection of central neurons through axons or axon terminals by this serotype is generally negligible ([@bib5; @bib14]). To ensure tight regulation of toxin expression, we used the FLEX system for irreversible Cre-dependent transgene activation ([@bib6]; [Figure 3](#fig3){ref-type="fig"}B). We made three injections at lumbar segments L3/L4/L5 of 300 nl each at a depth of 200--300 μm from the dorsal surface of the spinal cord. To enable post hoc verification of the injected area, we added an eGFP reporter AAV to the injection solution. Infected (eGFP+) cells were confined to the injected side with a rostrocaudal spread of about 3-4 mm ([Figure 3](#fig3){ref-type="fig"}C). Loss of inhibitory (Pax2+) neurons was confined to a similar region of the ipsilateral spinal cord ([Figure 3](#fig3){ref-type="fig"}D). To assess the efficacy and specificity of this approach, we compared the numbers of inhibitory (Pax2+) and excitatory (Lmx1b+ and PKCγ+) dorsal horn neurons as well as of ventral horn (vesicular acetylcholine transporter \[vAChT\]+) motoneurons after AAV.flex.DTA injection in GlyT2::Cre+ and GlyT2::Cre− mice. Four days after intraspinal injection, the number of Pax2+ spinal neurons was reduced by 46.5% ± 4.0% in GlyT2::Cre+ mice relative to GlyT2::Cre-- mice (one-way ANOVA, F(2,33) = 59.1, followed by Bonferroni post hoc test, p \< 0.001) ([Figures 3](#fig3){ref-type="fig"}E and 3I). At day 26, the loss of inhibitory neurons was only slightly larger (59.9% ± 6.0%, p = 0.15). Ablation was most pronounced in laminae III/VI, where 65.4% ± 1.1% (one-way ANOVA, F(2,33) = 84.1, Bonferroni post hoc test, p \< 0.001) of all inhibitory neurons were lost by day 4 ([Figure 3](#fig3){ref-type="fig"}I). Inhibitory interneuron loss in laminae I/II was less pronounced but still significant (17.5% ± 6.2% at day 4, one-way ANOVA, F(2,33) = 27.6, followed by Bonferroni post hoc test, p \< 0.001). This is in good agreement with our observation that only about 20% of the superficial inhibitory neurons are GlyT2::Cre+ compared with more than 80% in the deep dorsal horn. No loss of excitatory dorsal horn neurons or motoneurons was detected ([Figures 3](#fig3){ref-type="fig"}F--3H and 3J--3L). This demonstrates not only that Cre-dependent ablation via AAV.flex.DTA was specific to glycinergic neurons but also rules out a secondary loss of neurons through excitotoxicity triggered by diminished inhibition.

Changes in Inhibitory Synaptic Transmission after Local Glycinergic Neuron Ablation {#sec2.4}
-----------------------------------------------------------------------------------

We next employed a combination of electrophysiology and optogenetics to quantify changes in inhibitory synaptic transmission onto laminae I/II neurons caused by glycinergic neuron ablation ([Figure 4](#fig4){ref-type="fig"}). We used horizontal spinal cord slices prepared from vGAT::ChR2-eYFP BAC transgenic mice ([@bib70]), which express an optimized channelrhodopsin (ChR-H134R) fused to a fluorescent reporter (eYFP) under the transcriptional control of the *vGAT* gene (i.e., in all inhibitory, GABAergic, and glycinergic neurons). For an electrophysiological characterization of light-induced action potential firing in dorsal horn glycinergic neurons and inhibitory synaptic transmission in these mice, see [Figure S4](#app2){ref-type="sec"}. We crossed vGAT::ChR2-eYFP mice with GlyT2::Cre+ mice to obtain GlyT2::Cre+;vGAT::ChR2-eYFP double transgenic and GlyT2::Cre-;vGAT::ChR2-eYFP control mice. Both strains underwent the same AAV.flex.DTA injections as for the morphological experiments ([Figures 4](#fig4){ref-type="fig"}Aa and 4Ab). Slices were prepared from the lumbar spinal cords 4 days after AAV.flex.DTA injection, and brief (4-ms) blue light stimuli were applied to evoke inhibitory postsynaptic currents (IPSCs). IPSCs were recorded from photocurrent-negative (i.e., presumed excitatory) neurons in the superficial dorsal horn (laminae I/II). In GlyT2::Cre-;vGAT::ChR2-eYFP mice, IPSCs had mean amplitudes of 1.39 ± 0.41 nA (n = 21), whereas those in GlyT2:Cre+;vGAT::ChR2-eYFP mice were only 0.62 ± 0.10 nA (n = 23) ([Figures 4](#fig4){ref-type="fig"}Ac and 4Ad). To test whether the remaining IPSCs originated from purely GABAergic neurons, we determined the relative contribution of glycine and GABA to the IPSC in GlyT2::Cre+ and GlyT2::Cre-- mice after AAV.flex.DTA injection ([Figure 4](#fig4){ref-type="fig"}B). We found that, in both strains of mice, the glycine receptor antagonist strychnine blocked on average more than 70% of the total IPSC amplitude (73.0% ± 3.5%, n = 12, and 78.5% ± 3.9%, n = 15 for GlyT2::Cre-- and GlyT2::Cre+ mice, respectively; p \< 0.05, unpaired t test), whereas the remaining portion was blocked by the GABA~A~ receptor antagonist bicuculline. Changing the order of strychnine/bicuculline application did not change the glycine/GABA ratio. These data indicate that most of the fast inhibitory synaptic input onto the recorded neurons came from mixed glycine/GABAergic neurons.

Local Ablation of Glycinergic Neurons Elicits Mechanical, Heat, and Cold Hypersensitivity and Signs of Spontaneous Pain {#sec2.5}
-----------------------------------------------------------------------------------------------------------------------

GlyT2::Cre+ mice exhibited hypersensitivity and spontaneous aversive behaviors as early as 24 hr after intraspinal injection with AAV.flex.DTA ([Figure 5](#fig5){ref-type="fig"}). To characterize this phenotype quantitatively, we assessed GlyT2::Cre+ and GlyT2::Cre-- littermates in a battery of behavioral tests. In the von Frey test for mechanical sensitization, GlyT2::Cre+ mice showed a significant reduction in paw withdrawal thresholds (PWTs), whereas no change was observed in GlyT2::Cre-- mice ([Figure 5](#fig5){ref-type="fig"}A; for statistics, see figure legend). From day 2 post-injection onward, PWTs of GlyT2::Cre+ mice were reduced significantly compared with the baseline (repeated measures ANOVA, F(13,130) = 17.5; least significant difference (LSD) post hoc test, p \< 0.01), reaching a minimum 5 days after virus injection. From day 13 onward, PWTs recovered significantly toward the baseline (LSD post hoc test, p \< 0.01 for day 5 versus day 13 or later), suggesting the presence of compensatory processes. A similar sensitization process was observed for heat and noxious cold stimuli ([Figures 5](#fig5){ref-type="fig"}B and 5C). Nociceptive thresholds for contralateral paws of both GlyT2::Cre+ or GlyT2::Cre-- mice remained virtually unchanged for all three stimuli ([Figures S5](#app2){ref-type="sec"}A--S5C; for statistics, see figure legends).

Inhibitory neurons also play an important role in ventral motor circuits. To demonstrate that targeting of glycinergic interneurons did not cause confounding motor impairment, we assessed motor performance on an accelerating rotarod. GlyT2::Cre+ mice showed a slight progressive decrease in the maximum tolerated speed over 25 days ([Figure 5](#fig5){ref-type="fig"}D), but this did not match the time course of neuronal death or hyperalgesia.

In addition to hyperalgesia, we also observed signs of spontaneous discomfort that included flinching, licking/biting, and limb guarding/protection of the ipsilateral hindlimb. From 3--4 days post-injection, localized hair loss and skin lesions became apparent on the virus-injected side ([Figure 5](#fig5){ref-type="fig"}E). In the majority of cases, the area of hair removal extended along the thigh, closely matching the dermatomes corresponding to the AAV.flex.DTA-injected spinal segments. The contralateral side showed no evidence of hypersensitivity or hair loss and lesions. Similarly, AAV.flex.DTA-injected GlyT2::Cre-- mice remained completely normal. To assess spontaneous aversive behaviors, we quantified paw flinches in AAV.flex.DTA-injected mice and the time the animals spent licking/biting the affected limb. In GlyT2::Cre+ mice, we observed a significant increase in flinching and the time spent licking/biting, which peaked around 4 days after injection ([Figure 5](#fig5){ref-type="fig"}F). After day 4, the frequency of flinching decreased over the course of the remaining experiment, mirroring the recovery from thermal and mechanical hyperalgesia.

We next investigated the expression of c-*fos*, a marker of neuronal activation, in AAV.flex.DTA-injected mice as an additional non-behavioral readout. We harvested the spinal cords 24 hr after the last day of behavioral testing and immunostained horizontal sections of the virus-injected segments. The number of c-*fos*+ somata was significantly increased in GlyT2::Cre+ mice compared with GlyT2::Cre-- mice ([Figure 5](#fig5){ref-type="fig"}G). The c-*fos*+ neurons were evenly distributed within laminae I--IV, and a few positive somata were located in laminae V and VI. We observed few c-*fos*+ neurons on the contralateral side or in sections from GlyT2::Cre-- mice. A large increase in the number of labeled soma was seen after 4 days (76.6 ± 37 in Cre+ versus 10.8 ± 5.4 in Cre-- mice). By the end of the experiment, the number of c-*fos*+ neurons had decreased (19.1 ± 9 in Cre+ versus 1.6 ± 1.4 in Cre-- mice). The changes in c-*fos* expression therefore mirrored the results of the behavioral experiments.

Tetanus Toxin-Mediated Synaptic Silencing Recapitulates Behavioral Effects of Cell Ablation {#sec2.6}
-------------------------------------------------------------------------------------------

Viral infection and neuronal cell death activate microglia. An upregulation of the microglia marker IBA1 was indeed observed following ablation of glycinergic neurons with AAV.flex.DTA ([Figure S6](#app2){ref-type="sec"}). It has been shown previously that activation of dorsal horn microglia alone is sufficient to cause pain sensitization ([@bib15; @bib18; @bib58]). We therefore generated a second AAV (AAV.flex.TeLC) for Cre-dependent expression of tetanus toxin light chain (TeLC), which silences neurons by preventing vesicular transmitter release ([@bib56]). As expected, dorsal horn injection of AAV.flex.TeLC did not cause loss of spinal neurons ([Figures 6](#fig6){ref-type="fig"}A--6H), and no difference in IBA1 expression was observed between GlyT2::Cre+ and GlyT2::Cre-- mice after AAV.flex.TeLC injection ([Figure S6](#app2){ref-type="sec"}). Following AAV.flex.TeLC injection, GlyT2::Cre+ mice developed strong mechanical, heat, and noxious cold sensitization and exhibited localized hair loss and lesions (see legend for [Figure 7](#fig7){ref-type="fig"} for statistics). They also showed a significant increase in flinching and licking/biting behavior ([Figures 7](#fig7){ref-type="fig"}A--7E). Sensitization began to decrease from day 10 onward. We also found a significant increase in the number of c-*fos*+ cells 4 days and 26 days after injection of AAV.flex.TeLC ([Figure 7](#fig7){ref-type="fig"}F). No changes were seen in the contralateral paw ([Figure S5](#app2){ref-type="sec"}). The results obtained with tetanus toxin-mediated silencing therefore closely mirrored the effects of AAV.flex.DTA-mediated cell ablation.

Local Pharmacogenetic Activation of Dorsal Horn Glycinergic Neurons Mitigates Neuropathic Hyperalgesia {#sec2.7}
------------------------------------------------------------------------------------------------------

Our observation that glycinergic neurons serve a critical role in maintaining a physiological level of pain sensitivity prompted us to test whether exogenous activation of glycinergic neurons ameliorates chronic pain. To this end, we employed a pharmacogenetic approach ([@bib4]) and injected GlyT2::Cre;GlyT2::eGFP double-transgenic mice with AAV.flex.hM3Dq-mCherry, targeted to the left L3--L5 spinal segments. AAV.flex.hM3Dq encodes an engineered G protein-coupled receptor that renders Cre-expressing neurons responsive to activation by clozapine N-oxide (CNO) ([@bib3]; [Figure 8](#fig8){ref-type="fig"}A). We verified expression of hM3Dq-mCherry in the somata and neurites of GlyT2::eGFP+ neurons 2 weeks post-injection ([Figure 8](#fig8){ref-type="fig"}B). Transduced neurons were largely confined to lamina III/VI of the dorsal horn. No mCherry+ cell bodies were found in the ipsilateral ventral horn or on the contralateral side.

One week after virus injection, a unilateral neuropathic sensitization of the hindpaw ipsilateral to the side of virus injection was induced through a chronic constriction injury (CCI) of the sciatic nerve ([@bib8]). On day 7 after CCI surgery, we injected CNO (1 mg/kg, i.p.\]) or vehicle and assessed mechanical (von Frey) paw withdrawal thresholds for 5 hr. Within 1-2 hr after CNO administration, mechanical sensitivity decreased significantly in drug-treated but not vehicle-treated GlyT2::Cre+ mice ([Figure 8](#fig8){ref-type="fig"}C). Vehicle-injected mice showed no improvement over the testing period. We also tested whether activation of glycinergic neurons would reduce responses to acute noxious stimuli ([Figure 8](#fig8){ref-type="fig"}D). CNO prolonged withdrawal latencies upon heat and noxious cold stimulation more than 2-fold in naive AAV.flex.hM3Dq-injected GlyT2::Cre mice. Similarly, CNO reduced the number of escape responses upon pinprick stimulation of the hindpaw. To exclude muscle relaxation as a confounder, we assessed the performance of CNO and vehicle-injected CCI mice in the horizontal wire test and found no difference ([Figure 8](#fig8){ref-type="fig"}E). Taken together, these results demonstrate that activation of dorsal horn glycinergic neurons effectively alleviates neuropathic hyperalgesia.

Dorsal Horn Glycinergic Neurons Control Histamine- or Chloroquine-Induced Itch {#sec2.8}
------------------------------------------------------------------------------

GlyT2::Cre+ mice injected with AAV.flex.DTA or AAV.flex.TeLC not only developed long-lasting thermal and mechanical hypersensitivity but also displayed excessive localized licking and biting behavior leading to hair removal and skin lesions. This behavior is reminiscent of changes typically seen with chronic itch ([@bib2; @bib47]). We therefore tested whether mice would respond more strongly to pruritic stimuli after local spinal ablation of glycinergic neurons. These experiments did not yield conclusive results, probably because the spontaneous aversive behavior was too intense to detect further increases. As an alternative strategy, we examined whether pharmacogenetic activation of spinal glycinergic neurons would attenuate responses to puritic stimuli. To this end, we again injected GlyT2::Cre+ mice with AAV.flex.hM3Dq-mCherry. Two weeks after virus injection, their ipsilateral hindpaws were injected intracutaneously with either chloroquine or histamine ([Figure 8](#fig8){ref-type="fig"}F). Compared with vehicle, CNO significantly reduced the number of flinching and biting bouts induced by the injection of histamine or chloroquine. This final set of experiments indicates that spinal glycinergic neurons control not only pain but also itch transmission.

Discussion {#sec3}
==========

In this study, we used viral vector-mediated neuron manipulation to address a possible contribution of local glycinergic dorsal horn neurons to pain and itch control. The results from the comprehensive set of experiments involving local ablation or silencing of these neurons demonstrate that compromising their function induces an exaggerated abnormal sensitivity to mechanical, heat, and cold stimuli and triggers behavioral changes reminiscent of spontaneous pain and itch. Conversely, pharmacogenetic excitation of the same neurons alleviated neuropathic pain and itch.

Vector-Mediated Ablation as a Tool of Interneuron Manipulation {#sec3.1}
--------------------------------------------------------------

Clostridial toxins are highly versatile tools to manipulate cell function. In this study, we used the catalytic subunits of diphtheria toxin or tetanus toxin to locally ablate or silence glycinergic neurons. Cell-type-specific manipulation through diphtheria toxin or tetanus toxin can be achieved through different strategies. Expression as Cre-dependent germline transgenes is well established ([@bib43]) but would have led to global ablation of glycinergic neurons early in development and likely to subsequent early death ([@bib22]). [@bib13] introduced a method for inducible cell-type-specific ablation involving Cre-dependent expression of the diphtheria toxin receptor followed by local injection of diphtheria toxin. However, because GlyT2::Cre is transiently active in superficial dorsal horn neurons that are not glycinergic in the adult, this approach would still have lacked specificity. To circumvent these problems, we chose the viral approach, which enables local manipulation and avoids undesired effects originating from transient Cre expression during development.

Glycine Is the Dominant Inhibitory Neurotransmitter in Pain- and Itch-Controlling Spinal Circuits {#sec3.2}
-------------------------------------------------------------------------------------------------

Glycinergic neurons of the spinal dorsal horn are most abundant in lamina III and deeper, whereas only relatively few glycinergic neurons are found in the superficial layers (lamina I/II) ([@bib27; @bib44; @bib60; @bib68]). They are therefore relatively sparse in the laminae innervated by primary nociceptive fibers and much more frequent in the deep dorsal horn, where mainly non-nociceptive mechanosensitive fibers terminate. Indeed, our results demonstrated strong innervation by myelinated presumed non-nociceptive neurons ([Figure 2](#fig2){ref-type="fig"}). The concentration of glycinergic neurons in the deep dorsal horn has led to the suggestion that their dysfunction might primarily induce touch-evoked pain (also known as allodynia) ([@bib37; @bib39]). Our results also point to a critical role of glycinergic neurons in the processing of noxious thermal and mechanical input. Such a more general role in pain control is consistent with the results from our optogenetic experiments, which demonstrate that most of the inhibitory input onto superficial dorsal horn neurons is glycinergic (see also [@bib31]). The presence of strong glycinergic inhibition in the superficial dorsal horn is also consistent with a dense expression of glycine receptors of the α3 subtype at this site ([@bib26]) and the abundance of GlyT2-positive neuropil ([@bib68]). In fact, it has been shown recently that positive allosteric modulators of dorsal horn glycine receptors effectively reverse pathological pain states ([@bib37; @bib65; @bib66]).

Activation of Spinal Glycinergic Neurons Effectively Alleviates Neuropathic Pain {#sec3.3}
--------------------------------------------------------------------------------

Chronic pain is accompanied by states of diminished synaptic inhibition of dorsal horn neurons. This disinhibition is widely believed to contribute to pain hypersensitivity and to spontaneous pain sensations ([@bib69]). A variety of different mechanisms, including reduced expression of the GABA synthesizing enzyme GAD-65 ([@bib40; @bib50]), reduced release of GABA and/or glycine ([@bib41]) and reduced responsiveness of postsynaptic glycine receptors ([@bib1; @bib26]), have been proposed as mechanisms of diminished inhibition. Our finding that glycinergic neuron ablation or silencing induces thermal and mechanical sensitization and spontaneous pain behaviors is fully in line with this concept. Another process linking peripheral nerve damage to reduced inhibition in the dorsal horn is the microglia-mediated and brain-derived neurotrophic factor-dependent downregulation of the potassium-chloride co-exporter KCC2 ([@bib16; @bib17]). Reduced expression of this transporter causes a depolarizing shift of the reversal potential of glycinergic and GABAergic currents. It has been proposed that this shift may even reach the threshold of action potentials and would, thereby, change the effect of GABAergic and glycinergic input from inhibition to excitation ([@bib16]). Our experiments employing pharmacogenetic activation of local glycinergic neurons suggest that these neurons retain their inhibitory action even in the presence of neuropathy. This result is consistent with the reversal of neuropathic pain sensitization by drugs that potentiate the activation of GABA~A~ receptors in the dorsal horn ([@bib33]) and by transplantation of GABAergic precursor neurons into the dorsal horn of neuropathic mice ([@bib11]).

Contribution of Neuronal Death or Virus-Activated Microglia? {#sec3.4}
------------------------------------------------------------

Neuronal cell death is a strong activator of microglia. It was therefore important to investigate whether diphtheria toxin-induced cell death would activate microglia and whether this microglia activation would, in turn, contribute to pain sensitization. Quantification of IBA1 immunoreactivity in AAV.flex.DTA-injected dorsal horns demonstrated strong microglia activation in GlyT2::Cre+ mice and, to a much lesser degree, in GlyT2::Cre-- mice. However, AAV.flex.DTA-mediated neuronal death and AAV.flex.TeLC-mediated silencing of the same neuron types led to virtually identical pain phenotypes despite strong differences in the degree of IBA1 upregulation. Hence, the pain was due to the ablation or silencing of glycinergic neurons rather than due to secondary microglia activation. Microinjections into the spinal cord are alone sufficient to induce microglia activation ([@bib28]). We found similar degrees of microglial IBA1 upregulation in AAV.flex.TeLC-injected GlyT2::Cre-- and GlyT2::Cre+ mice. However, pain sensitization occurred only in GlyT2::Cre+ mice; i.e., under conditions in which the glycinergic neurons were silenced. Pain sensitization by microglia may therefore require a specific microglial activation state ([@bib24; @bib25; @bib59]).

Spinal Plasticity Ameliorating Long-Lasting Pain? {#sec3.5}
-------------------------------------------------

An unexpected finding in our behavioral experiments was the partial recovery from pain sensitization after glycinergic neuron ablation or silencing. The results discussed above largely rule out recovery from microglia-induced pain sensitization as the underlying mechanism. Virus inactivation, e.g., through DNA methylation ([@bib12]), could have accounted for part of the recovery from TeLC-mediated neuronal silencing. However, recovery occurred similarly in ablation experiments, leaving neuronal and synaptic plasticity as the most likely mechanisms. Such compensatory plasticity may involve a downregulation of excitatory input, changes in descending pain control, or the sprouting of inhibitory axons surviving in the ablated area. It is certainly appealing to think that a facilitation of such mechanisms might be exploited therapeutically in chronic pain states.

Control of Itch-Transmitting Circuits by Glycinergic Neurons {#sec3.6}
------------------------------------------------------------

The extensive licking and biting behavior and hair loss after glycinergic neuron ablation or silencing together with the suppression of itch responses by activation of local glycinergic neurons indicate that these neurons control not only pain but also itch processing. The intense innervation of glycinergic dorsal horn neurons by myelinated primary sensory neurons fits nicely with the concept of the gate control theory for pain, where light touch has been proposed to reduce transmission of painful signals. However, 9% of the retrogradely labeled primary sensory neurons were peptidergic or bound IB4. These presumed nociceptors likely innervate the small population of glycinergic neurons in the superficial dorsal horn. It is tempting to speculate that these primary sensory fibers and glycinergic neurons underlie the reduction of itch sensations by painful stimulation ([@bib19; @bib62]).

Two previous reports ([@bib30; @bib47]) have identified subpopulations of inhibitory dorsal horn neurons as a source of spinal itch inhibition. These subpopulations depend on the transcription factor Bhlhb5 and express galanin and/or nNOS ([@bib30]). In the rat, many of the inhibitory nNOS-positive neurons are also glycinergic ([@bib35]), whereas most of the galanin+ neurons are likely purely GABAergic ([@bib52]). Our studies ([Figure S2](#app2){ref-type="sec"}) indicate that this is also true for the mouse. Therefore, the ablation of the nNOS+ subpopulation of glycinergic neurons may underlie the induction of itch behavior observed in our study. On the other hand, [@bib30] provided evidence that the inhibition of itch by dorsal horn interneurons depends on the action of the opioid peptide dynorphin, which is found in the galanin+ subpopulation of purely GABAergic (non-glycinergic) interneurons ([@bib49]). The latter scenario would suggest the presence of at least two different subsets of dorsal horn inhibitory neurons controlling itch.

Future Implications {#sec3.7}
-------------------

This study establishes glycinergic neurons of the dorsal horn as critical elements of a spinal gate for pain and itch signals. It is likely that inhibitory dorsal horn neurons contribute to other spinal cord functions in addition to pain and itch control. Such functions may include improvement of tactile acuity through lateral inhibition ([@bib29]) or of posture and gait control through feedback and feedforward inhibition in motor circuits ([@bib23]). It will be interesting to investigate whether these different functions involve distinct glycinergic subpopulations. The virus-based techniques established here constitute a versatile set of tools to address these questions.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

GlyT2::eGFP (Tg(Scl6a5-EGFP)1Uze) and vGAT::ChR2-eYFP (Tg(Slc32a1-COP4^∗^H134R/EYFP)8Gfng) mice have been described previously ([@bib68; @bib70]). GlyT2::Cre (Tg(Slc6a5-Cre)1Uze) mice were generated following the same strategy as used previously for GlyT2::eGFP mice ([@bib68]). Control experiments were performed in *Gad67*^eGFP^ (Gad1^tm1Tama^) mice ([@bib57]) and *ROSA26*^lacZ^ (Gt(ROSA)26Sor) mice ([@bib54]). For details, see [Supplemental Experimental Procedures](#app2){ref-type="sec"}. All procedures involving animals were approved by the Veterinäramt des Kantons Zürich (license numbers 64/2010, 75/2010, 75/2013, and 86/2013).

Immunohistochemistry and Image Analysis {#sec4.2}
---------------------------------------

Immunohistochemistry was performed as described previously ([@bib46]). For information on antibodies, see [Supplemental Experimental Procedures](#app2){ref-type="sec"}. Fluorescent images were acquired on a Zeiss LSM710 Pascal confocal microscope. For quantitative analyses, sections were prepared from at least three animals, and at least three sections were analyzed per animal. Numbers of immunoreactive cells were determined using the ImageJ Cell Counter plugin. Controlled mean fluorescent intensity (CMTF) was quantified using ImageJ.

Virus Production and Injections {#sec4.3}
-------------------------------

AAV.flex.hM3Dq-mCherry and AVV.eGFP were obtained from the University of North Carolina (UNC) vector core and Penn Vector Core (Perelman School of Medicine, University of Pennsylvania), respectively. All other AAV vectors were cloned in-house and packaged at the Penn Vector Core. The cell lines required for production of EnvA.RabiesΔG-eGFP were obtained from Dr. Edward Callaway (Salk Institute). Propagation was done following the protocol by [@bib42].

Virus injections were made in mice anesthetized with 2%--5% isoflurane and immobilized on a motorized stereotaxic frame (David Kopf Instruments and Neurostar). Lumbar vertebrae L4 and L5 were exposed, and the vertebral column was fixed using a pair of spinal adaptors. Injections were made at a rate of 30 nl/min with glass micropipettes (tip diameter, 30--40 μm) attached to a 10-μl Hamilton syringe.

Electrophysiology and Optogenetics {#sec4.4}
----------------------------------

Transverse lumbar spinal cord slices were cut from 25- to 28-day-old vGAT::ChR2-eYFP;GlyT2::Cre double-transgenic and vGAT::ChR2-eYFP control (GlyT2::Cre--) mice injected at lumbar levels L3--L5 with a combination of AAV.flex.DTA and AAV.mCherry. Whole-cell patch-clamp recordings were made at room temperature from excitatory superficial dorsal horn neurons. Light-evoked IPSCs were elicited at a frequency of 5min by wide-field illumination of the dorsal horn (473 ± 5 nm wavelength, 2.7 mW, 4 ms).

Behavioral Analyses {#sec4.5}
-------------------

Adult male GlyT2::Cre+ and GlyT2::Cre-- mice (7--8 weeks old) received three unilateral injections at lumbar levels L3--L5 with AAV.flex.DTA, AAV.flex.TeLC, or AAV.flex.hM3Dq-mCherry. In GlyT2::Cre+ and GlyT2::Cre− mice injected with AAV.flex.DTA and AAV.flex.TeLC, mechanical, heat, and noxious cold sensitivity were assessed for up to 26 days after virus injection. Pharmacogenetic experiments with CNO (1 mg/kg, i.p.) were done in AAV.flex.hM3Dq-mCherry-injected mice 7 days after CCI surgery (i.e., 14 days after virus injection). Itch responses (flinches and biting bouts) were elicited through intracutaneous injections of chloroquine (10 μl of 8 mg/ml) or histamine (10 μl of 10 mg/ml) into one hindpaw. Animals were videotaped for 30 min, and responses were analyzed offline. The horizontal wire test and the rotarod test were used to assess muscle relaxation and motor impairment, respectively.
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====================
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![Generation and Characterization of GlyT2::Cre BAC Transgenic Mice\
(A) GlyT2::Cre BAC transgenic mice were generated from a BAC DNA clone containing the mouse *GlyT2* locus, of which exon 2 (E2) was modified by the insertion of a Cre expression cassette.\
(B) Comparison of Cre-mediated recombination and GlyT2::eGFP expression in GlyT2::Cre;GlyT2::eGFP;*Rosa26*^LacZ^ triple-transgenic mice using anti-β-gal (red) and anti-eGFP (green) antibodies.\
(C) Percentage of β-gal and eGFP double-positive neurons (mean ± SD).\
(D) Same as (B) but analysis of co-expression of Cre with eGFP.\
(E) Quantification of (D).\
(F) Same as (B) but analysis of co-expression of Cre with Pax2.\
(G) Quantification of (F). The two left columns refer to the entire spinal cord cross section (laminae I--X), whereas the two right columns show results for the superficial dorsal horn (laminae I/II) and the rest of the spinal cord (≥III) separately.\
(H) Higher magnification of the lamina II/III border (the dashed area indicated in F).\
Scale bars, 100 μm (B) and 50 μm (F).](gr1){#fig1}

![Innervation of Spinal Glycinergic Neurons by Primary Sensory Neurons\
(A) Schematic of the injection paradigm enabling monosynaptic retrograde tracing from GlyT2::Cre+ spinal neurons. A Cre-dependent AAV coding for the avian sarcoma virus receptor and the rabies G protein (AAV.flex.TVA-2A-RabG, (1)) was injected 14 days prior to injection with an EnvA-pseudotyped G-deleted eGFP rabies virus (EnvA.RabiesΔG-eGFP, (2)).\
(B) Schematic of the genomes of the AAV and rabies virus used in this experiment.\
(C) A section of a DRG containing numerous retrogradely infected neurons was stained with antibodies against NeuN (blue) and eGFP (green).\
(D and E) Immunohistological analysis of retrogradely infected DRG neurons. Shown are NF200 (red), eGFP (green), and IB4 (blue) (D) or antibodies against eGFP (green) and CGRP (red).\
(F) Relative abundance of NF200+, CGRP+, or IB4+ cells among the eGFP+ (retrogradely infected) population of DRG neurons. Eight mice were analyzed.\
Scale bars, 100 μm (C) and 50 μm (D).](gr2){#fig2}

![Specific Loss of Inhibitory Interneurons after AAV.flex.DTA Injection into the Dorsal Horn of GlyT2::Cre+ Mice\
(A) AAV.flex.DTA was injected into the lumbar dorsal horn of GlyT2::Cre+ GlyT2::Cre− littermates.\
(B) The AAV.flex.DTA genome. The expression of DTA is driven by the EF1a promotor (EF1a) and depends on Cre-mediated irreversible inversion of the DTA coding sequence.\
(C) Green fluorescence illustrates virus spread (of an AAV.eGFP) following three separate unilateral injections into the lumbar spinal cord at levels L3--L5.\
(D) Sagittal sections of a spinal cord after injection of AAV.flex.DTA illustrate a marked reduction in the number of Pax2+ cells on the ipsilateral side (left) but not on the contralateral side (right).\
(E) Compared with AAV.flex.DTA-injected GlyT2::Cre− control mice, a clear loss of Pax2+ cells was observed 4 days after injection of AAV.flex.DTA on the injected side of GlyT2::Cre+ mice. Fluorescence signals detected by confocal microscopy were false-colored in green.\
(F--H) Same as (E) but analysis of Lmx1b+ excitatory dorsal horn neurons (F), PKCγ+ excitatory dorsal horn neurons (G), and vAChT+ motoneurons (H).\
(I--L) Quantification (mean ± SD). At least three to four horizontal sections per mouse centered around the L4 injection site were used for quantification.\
(I) ^∗∗∗^p \< 0.001 versus baseline, one-way ANOVA, F(2,33) = 59.1, followed by Bonferroni post hoc test.\
(I--K) No significant differences in cell counts were found for Lmx1b+, PKCγ+, or vAChT+ neurons (p \> 0.20). Dashed lines indicate gray matter border (E--H) and borders of lamina II (F and G).\
Scale bars, 1 mm (C and D) and 100 μm (E and H).](gr3){#fig3}

![Inhibitory Synaptic Transmission after Local Glycinergic Interneuron Ablation\
(Aa--Ad) IPSCs evoked by 4-ms, 473-nm light stimulation recorded in slices prepared from mice 4 days after AAV.flex.DTA injection.\
(Aa) Schematic illustrating the recording situation.\
(Ab) Distribution of mCherry expression observed after unilateral injection of AAV.mCherry together with the AAV.flex.DTA.\
(Ac) Average IPSC traces per cell (gray) of 21 neurons from GlyT2::Cre− (left) and 23 neurons from GlyT2::Cre+ mice (right). Black traces represent the average IPSC for each genotype.\
(Ad) Statistics. Dots represent average IPSC amplitudes of individual cells. Horizontal and vertical lines indicate mean values and SEM. ^∗∗^p \< 0.01 (unpaired t test).\
(Ba--Bc) Contribution of glycine and GABA to the IPSC amplitude in AAV.flex.DTA-injected GlyT2::Cre+ and GlyT2::Cre− mice.\
(Ba) Time course of the experiment. Strychnine (stry, 0.5 μM) and a combination of strychnine (0.5 μM) and bicuculline (bic, 20 μM) were applied 6 and 12 min after the recording started.\
(Bb) The top traces show averages of 10 consecutive traces recorded under control conditions during application of strychnine and in the combined presence of strychnine and bicuculline. The normalized traces below illustrate the difference in the decay kinetics of the GABAergic and glycinergic IPSC components.\
(Bc) Statistics. Dots represent the glycinergic IPSC component in individual cells. Horizontal and vertical lines indicate mean values and SEM, p = 0.49 (unpaired t test), n = 12 and 15 for GlyT2::Cre- and GlyT2::Cre+ mice, respectively.](gr4){#fig4}

![Mechanical, Heat, and Cold Hyperalgesia and Spontaneous Aversive Behaviors Induced after Local Ablation of Glycinergic Dorsal Horn Neurons\
(A) Reduction in mechanical PWT (mean ± SEM) over time after unilateral injection of AAV.flex.DTA into GlyT2::Cre+ mice and GlyT2::Cre− littermates. Two-way repeated measures ANOVA revealed a significant time x genotype interaction (F(13,221) = 13.9, p \< 0.001), and post hoc comparisons show significant differences between genotypes at 3--25 days (p \< 0.01, n = 11 and 8 for GlyT2::Cre+ and GlyT2::Cre− mice, respectively). baseline.\
(B) Heat hyperalgesia. Two-way repeated measures ANOVA revealed a significant time x genotype interaction (F(13,221) = 4.04, p \< 0.001). Significant differences between genotypes were found for time points 3--10 days (p \< 0.01, n = 11 and 8 for GlyT2::Cre+ and GlyT2::Cre− mice, respectively).\
(C) Cold hyperalgesia. Two-way repeated measures ANOVA revealed a significant time x genotype interaction (F(13,143) = 2.81, p = 0.001). Significant differences were found between genotypes for time points 7--16 days (p \< 0.01, n = 6 and 7 for GlyT2::Cre+ and GlyT2::Cre− mice, respectively).\
(D) Accelerating rotarod performance (maximum tolerated rounds per minute \[RPM\]). Repeated measures ANOVA, F(4,40) = 4.14; p = 0.007 (n = 11). Post hoc LSD test revealed a significant change from the baseline for day 25 only.\
(E) GlyT2::Cre+ mice, but not GlyT2::Cre− littermates, exhibited localized hair loss on the thigh ipsilateral to the virus injection (depicted here 26 days after virus injection).\
(F) Spontaneous aversive behaviors (flinches, left, and time spent licking/biting, right) in GlyT2::Cre+ mice and GlyT2::Cre− littermates (n = 7 each). Two-way repeated measures ANOVA revealed a significant time x genotype interaction for flinching (F(4,48) = 7.02, p \< 0.001), and time spent licking/biting (F(4,48) = 7.02, p \< 0.001). Significant differences between genotypes were found for days 4 and 10 (p ≤ 0.01 for both readouts). On day 25, the number of flinches and the time spent licking/biting were reduced significantly compared with day 4 (p \< 0.05).\
(G) c-*fos* expression in spinal cords of GlyT2::Cre+ mice and GlyT2::Cre− littermates 4 days after dorsal horn AAV.flex.DTA injection. ^∗∗∗^p \< 0.001, unpaired t test, n ≥ 9 sections from 3-4 different animals. Scale bar, 200 μm.\
Error bars indicate SEM in (A--D) and (F) and SD in (G).](gr5){#fig5}

![Expression of Tetanus Toxin Light Chain in Glycinergic Dorsal Horn Interneurons Does Not Cause Neuronal Death\
(A) No loss of Pax2 immunoreactive cells following AAV.flex.TeLC injection into GlyT2::Cre+ mice (images taken 4 days after virus injection).\
(B--D) No apparent loss of Lmx1b+ excitatory dorsal horn neurons (B), of PKCγ+ excitatory dorsal horn neurons (C), or of vAChT+ motoneurons (D) was detected.\
(E--H) Quantifications (percent relative to GlyT2::Cre−, mean ± SD). Scale bars, 100 μm (A and B).](gr6){#fig6}

![Local Silencing with Tetanus Toxin Light Chain of Glycinergic Dorsal Horn Neurons Recapitulates the Behavioral Effects of Diphtheria Toxin-Mediated Ablation\
(A) Mechanical hyperalgesia. Statistics: significant time x genotype interaction, F(10,140) = 12.4, p \< 0.001 (two-way repeated measures ANOVA). Post hoc comparisons show significant differences between genotypes at 2--24 days (p \< 0.01, n = 8 for both genotypes).\
(B) Heat hyperalgesia: significant time x genotype interaction (F(10,140) = 42.35, p \< 0.05). Significant differences between genotypes were found for time points 4--10 days (p \< 0.01, n = 8 for both genotypes).\
(C) Same as (B) but cold hyperalgesia. Repeated measures ANOVA (F(13,247) = 4.0, p \< 0.001). Significant differences between genotypes were found (p ≤ 0.01) for time points 4--16 days (n = 10 and 11 for GlyT2::Cre+ and GlyT2::Cre− mice, respectively).\
(D) Localized hair removal and skin lesions (26 days after AAV.flex.TeLC injection).\
(E) Spontaneous aversive behaviors (n = 5 and 6 for GlyT2::Cre+ and Cre− mice, respectively). ANOVA revealed significant differences for between subject effect (genotype) (F(1,9) = 48.3, p \< 0.001 and F(1,9) = 76.3 p \< 0.001 for flinching and licking/biting, respectively).\
(F) c-*fos* expression (images taken 4 days after AAV.flex.TeLC injection). ^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01, unpaired t test comparing the total number of c-*fos*+ cells from all laminae, n = 4--7.\
For more details, see [Figure 5](#fig5){ref-type="fig"}. Error bars indicate SEM in (A--C) and (E) and SD in (F). Scale bar, 200 μm.](gr7){#fig7}

![Pharmacogenetic Activation of Spinal Glycinergic Neurons Ameliorates CCI-Induced Neuropathic Pain and Chloroquine- or Histamine-Induced Itch\
(A) Diagram illustrating the AAV genome containing the flex.hM3Dq-mCherry cassette.\
(B) Expression of hM3Dq in the spinal cord of GlyT2::Cre;GlyT2::eGFP double-transgenic mice is indicated by mCherry fluorescence. Expression is limited to the ipsilateral dorsal horn and is present in somata (see detail, bottom) and neurites of eGFP+ neurons. Scale bars, 200 μm (top) and 50 μm (bottom).\
(C) Antihyperalgesic effects. All experiments were made in GlyT2::Cre+ mice. AAV.flex.hM3Dq-mCherry was injected at day 0, CCI surgery was performed on day 7 on virus-injected mice, and vehicle or CNO (1 mg/kg, i.p.) was injected on day 14. Mechanical PWTs (g) were assessed using electronic von Frey filaments before CCI surgery (pre-CCI), after CCI surgery immediately before CNO/vehicle injection (post-CCI), for 5 hr after CNO/vehicle injection, and 1 day later (post-drug). Repeated measures ANOVA, F(6,66) = 4.47; p = 0.001 for treatment x time interaction. Post hoc comparisons revealed significant differences between CNO and vehicle-treated groups for time points 2 and 3 hr (n = 6 and 7 for vehicle and CNO, respectively).\
(D) Acute antinociceptive effects (repeated-measures ANOVA). Significant treatment effects were observed in the Hargreaves test (F(1,9) = 43.1, p \< 0.001 \[n = 5 and 6 for CNO and vehicle, respectively\]), for cold hyperalgesia (F(1,9) = 56.2, p \< 0.001 \[n = 6 and 5\]), and for pinprick stimulation (F(1,8) = 21.0, p = 0.002 \[n = 5 each\]).\
(E) Horizontal wire test. Repeated measures ANOVA (F(1,7) = 0.001, p = 0.98).\
(F) Blockade of chloroquine- and histamine-induced itch in AAV.flex.hM3Dq-mCherry-injected GlyT2::Cre+ mice by CNO. ^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01, unpaired t test, n = 7 for all four groups.\
All error bars indicate SEM.](gr8){#fig8}
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